

December 01, 2022

National Stock Exchange of India Limited,
Listing Department
Exchange Plaza, 5th Floor,
Bandra (E), Mumbai-400051

BSE Limited
Listing Department Corporate Relationship Department
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai-400001

Symbol: **ORCHIDPHARMA**

Scrip Code: **524372**

Subject: Corrigendum to the Press Release dated December 1, 2022 issued at 4.50 p.m. on BSE Listing Centre and 4.58 p.m. on NSE Digital Exchange (“Press Release”).

Dear Sir/Madam,

This is with reference to the Press Release issued by the Orchid Pharma Ltd (“**Company**”). Please note that the Press Release erroneously captures content extraneous to the decision taken at the Board meeting dated December 1, 2022 of the Company. Therefore, the Press Release is modified and replaced in its entirety with the content below.

“**New Delhi, 1st December 2022:** Orchid Pharma Ltd. (“**Company**”) today informed the exchanges that its Board has approved the Company’s Qualified Institutional Placement (“**QIP**”) programme to raise upto Rs.500 Crore, subject to approval of the shareholders.”

The same is also available on the website of the Company i.e. www.orchidpharma.com

You are requested to take the above on record.

Thanking You,
For **Orchid Pharma Limited**

Marina Peter
Company Secretary